Natco Pharma shines on getting nod from CDSCO for emergency use of Baricitinib tablets
Natco Pharma Limited has informed the bourses that it has received emergency use approval for Baricitinib tablets in strengths of 1 mg, 2 mg, and 4 mg from Central Drugs Standard Control Organisation (CDSCO), India. Baricitinib, combined with Remdesivir, is used for the treatment of COVID-19 positive patients.
Natco will be requesting a compulsory licence, based on emergency use and in light of the grave & serious public health emergency across India due to the pandemic. The company is ready to launch the product this week, so as to make the product available to all the patients across the country.
In April, the company had applied to CDSCO, India for the approval of phase-III clinical trial of Molnupiravir capsules for the treatment of COVID-19 positive patients. It is hoping that CDSCO would give emergency approval of this drug based on ‘compassionate use’ for patients.
Natco Pharma mainly operates through three key segments i.e. oncology, speciality pharma, cardiology & diabetology. Currently, in the US market, the company has 23 active commercial products while 5 ANDAs are in the pipeline.
With this, the stock of Natco Pharma was trading 4.3 per cent higher at Rs 935 from its previous close of Rs 896.65 on BSE.